Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New digital heart rehab could help patients recover at home

NCT ID NCT07590635

Disease control Sponsor: Haukeland University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests a 12-week home-based digital cardiac rehabilitation program for people with coronary artery disease. It aims to improve heart health, reduce hospital visits, and enhance quality of life, especially for older adults, women, and those with other health issues. The study will enroll 1000 participants across multiple centers in Norway.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
digital cardiac rehabilitation programme
What this could lead to
If successful, this could provide an effective home-based alternative to traditional cardiac rehab, making it accessible to more patients.
What could go wrong
This is a single trial with 1000 participants, and the digital approach may not work as well for all patients, especially those with limited tech skills.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2037

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult Norwegian (or Scandinavian) speaking patients (≥ 18 years) who have a Norwegian national identification number * With coronary artery disease after percutaneous coronary intervention * Living at home * Have internet available * Provide signed informed consent Exclusion Criteria: * Patients with cognitive impairment that may interfere with the ability to comply with the study protocol * Severe aortic stenosis * Severe arrhythmias * Expected lifetime less than one year as determined by study personnel * Otherwise clinically unstable * Not fully revascularized * Awaits percutaneous coronary intervention or coronary artery bypass graft surgery * Inability to comply with the study protocol due to any physical disability, somatic disease, or mental problems as determined by study personnel

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adherence, medication are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder Medication Adherence Psychological Well-Being

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adherence, medication Cardiac rehabilitation Comorbidities and coexisting conditions Continuity of patient care Coronary artery disease (CAD) Cost-benefit analysis Ehealth literacy ETHICS Health literacy Mental health Older adults (65 years and older) Secondary prevention of coronary heart disease Womens's health

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Haukeland University Hospital

    RECRUITING

    Bergen, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.